IN BRIEF
Many lipid nanoparticles lose potency as the RNA cargo becomes longer.
The team screened lipids from the start with a 5.7-kb mRNA and identified LC-1.
In mouse reporter models LC-1 reached up to 79% knockout in liver, 48% in brain and 27% in lung.
WHY IT MATTERS
Advanced gene editors require much longer RNA instructions than many experimental cargos, so a nanoparticle that looks good with short RNA can fail when carrying the real editor.
The study shows cargo size should be built into the design stage rather than checked only at the end.
WHAT IS NOW POSSIBLE
Cargo length becomes a design variable rather than an afterthought: screening with the RNA size the therapy actually needs produced a particle that retained an ordered, membrane-disrupting structure with large cargo and improved editing in vivo.
WHAT MADE IT POSSIBLE
A library of 384 lipids was screened directly with a 5.7-kb reporter mRNA. LC-1 retained stronger lipid-RNA interactions and an ordered fusogenic structure as cargo size increased.
THE STORY
Getting a gene editor into a cell is not only about finding a good nanoparticle; it also depends on how long the RNA instructions are. Many formulations lose potency just when the cargo becomes large enough to encode tools such as base editors.
The researchers reversed the usual workflow. Instead of selecting lipids with small RNAs and testing them later with a large editor, they screened 384 candidates using a 5.7-kilobase mRNA from the start.
The resulting formulation, LC-1, worked in vivo in mice through three administration routes. In reporter models it produced up to 79% Cas9 knockout in liver, 48% in brain and 27% in lung, outperforming benchmark formulations in the study.
The system also delivered base editors toward targets including PCSK9, CFTR R55X and Ube3a-ATS. That shows the advantage extends beyond a simple reporter, but it is not the same as correcting disease in people.
The result is therefore a preclinical delivery advance: it makes large RNA-encoded editors more practical across several animal tissues, while safety, dosing and therapeutic efficacy in humans remain untested.
WHAT WE KNOW
LC-1 emerged from screening with a 5.7-kb mRNA cargo. [1][2][3]
Editing was physically demonstrated in vivo in mouse liver, brain and lung.
Biologically relevant targets including PCSK9, CFTR R55X and Ube3a-ATS were also tested.
The study is peer reviewed in Nature Biotechnology.
WHAT WE DON'T KNOW
Whether the advantage persists in primates or humans.
What toxicity profile emerges at therapeutic or repeated doses.
How broadly the formulation generalizes across RNA sequences, editors and tissues.
Whether the molecular editing produces clinical benefit.
WHAT HAPPENS NEXT
Validation in larger animals, safety studies and disease-phenotype rescue are needed.
Cargo-size-informed screening can also be tested with other large editors and harder-to-reach tissues.
SOURCE TRACE
The team screened 384 ionizable lipids using a 5.7-kb ABE–NanoLuc reporter mRNA and identified LC-1 as the lead large-cargo formulation.
LC-1 achieved up to 79% Cas9-mediated knockout in liver, 48% in brain and 27% in lung in mouse reporter models.
LC-1 supported in-vivo base editing of PCSK9, CFTR R55X and Ube3a-ATS targets in the study's mouse experiments.
Mechanistic measurements showed LC-1 retained a more ordered fusogenic structure and stronger lipid-RNA interactions as mRNA size increased than benchmark formulations.
SOURCES
- Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editingOpen source
- Cargo size matters when designing lipid nanoparticles for delivery of large gene editorsOpen source
- Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editingOpen source
CURRENT EVIDENCE
VALIDATED EVIDENCE
Physical in-vivo delivery and genome editing in mice across liver, brain and lung routes.
WHAT WOULD CHANGE THIS?
- Failure to retain the LC-1 advantage in larger animals or with independent therapeutic cargos.
- Systemic or tissue-specific toxicity incompatible with useful dosing.
- Confirmation in primates or humans would move the result substantially closer to clinical medicine.